Cargando…

Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study

BACKGROUND: Early disease detection with a minimally invasive screening test will significantly increase effectiveness and decrease the cost of treatment. Here we propose a framework of a novel approach – Universal Screening Test (UST) for the detection of pathological processes in a particular orga...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheinerman, Kira S, Tsivinsky, Vladimir G, Umansky, Samuil R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867418/
https://www.ncbi.nlm.nih.gov/pubmed/24330742
http://dx.doi.org/10.1186/1479-5876-11-304
_version_ 1782296301677838336
author Sheinerman, Kira S
Tsivinsky, Vladimir G
Umansky, Samuil R
author_facet Sheinerman, Kira S
Tsivinsky, Vladimir G
Umansky, Samuil R
author_sort Sheinerman, Kira S
collection PubMed
description BACKGROUND: Early disease detection with a minimally invasive screening test will significantly increase effectiveness and decrease the cost of treatment. Here we propose a framework of a novel approach – Universal Screening Test (UST) for the detection of pathological processes in a particular organ system, organ, or tissue by RT-qPCR analysis of circulating cell-free miRNAs in plasma. As the first step towards assessing the feasibility of this concept, the present study was designed to analyze whether the same microRNAs (miRNAs) can detect various diseases of a particular organ system. METHODS: RNA was extracted from plasma using Trizol treatment and silica binding. Levels of miRNAs were measured by single target RT-qPCR. The following innovations have been tested and proven effective: (i) the use of organ system/organ/tissue-enriched miRNAs; (ii) the use of miRNAs associated with broad disease categories, such as cancer and inflammation, in combination with the organ-enriched miRNAs; and (iii) the use of “miRNA pairs” for selecting miRNA combinations with the highest sensitivity and specificity. RESULTS: Here we report biomarker miRNA pairs effectively differentiating (i) patients with pulmonary system diseases (asthma, pneumonia and non-small cell lung cancer) and gastrointestinal (GI) system diseases (Crohn’s disease, stages I/II esophageal, gastric and colon cancers) from controls, each with 95% accuracy; (ii) patients with a pathology of the pulmonary system from patients with a pathology of the GI system with 94% accuracy; and (iii) cancer patients (stages I/II esophageal, gastric, colon cancers, or non-small cell lung cancer) from patients with inflammatory diseases (asthma, pneumonia, or Crohn’s disease) with 93%-95% accuracy. CONCLUSIONS: The results obtained in the present study, along with the data reported by us and others previously, are encouraging and lay the ground for further investigation of the described approach for UST development.
format Online
Article
Text
id pubmed-3867418
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38674182013-12-19 Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study Sheinerman, Kira S Tsivinsky, Vladimir G Umansky, Samuil R J Transl Med Research BACKGROUND: Early disease detection with a minimally invasive screening test will significantly increase effectiveness and decrease the cost of treatment. Here we propose a framework of a novel approach – Universal Screening Test (UST) for the detection of pathological processes in a particular organ system, organ, or tissue by RT-qPCR analysis of circulating cell-free miRNAs in plasma. As the first step towards assessing the feasibility of this concept, the present study was designed to analyze whether the same microRNAs (miRNAs) can detect various diseases of a particular organ system. METHODS: RNA was extracted from plasma using Trizol treatment and silica binding. Levels of miRNAs were measured by single target RT-qPCR. The following innovations have been tested and proven effective: (i) the use of organ system/organ/tissue-enriched miRNAs; (ii) the use of miRNAs associated with broad disease categories, such as cancer and inflammation, in combination with the organ-enriched miRNAs; and (iii) the use of “miRNA pairs” for selecting miRNA combinations with the highest sensitivity and specificity. RESULTS: Here we report biomarker miRNA pairs effectively differentiating (i) patients with pulmonary system diseases (asthma, pneumonia and non-small cell lung cancer) and gastrointestinal (GI) system diseases (Crohn’s disease, stages I/II esophageal, gastric and colon cancers) from controls, each with 95% accuracy; (ii) patients with a pathology of the pulmonary system from patients with a pathology of the GI system with 94% accuracy; and (iii) cancer patients (stages I/II esophageal, gastric, colon cancers, or non-small cell lung cancer) from patients with inflammatory diseases (asthma, pneumonia, or Crohn’s disease) with 93%-95% accuracy. CONCLUSIONS: The results obtained in the present study, along with the data reported by us and others previously, are encouraging and lay the ground for further investigation of the described approach for UST development. BioMed Central 2013-12-11 /pmc/articles/PMC3867418/ /pubmed/24330742 http://dx.doi.org/10.1186/1479-5876-11-304 Text en Copyright © 2013 Sheinerman et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sheinerman, Kira S
Tsivinsky, Vladimir G
Umansky, Samuil R
Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
title Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
title_full Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
title_fullStr Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
title_full_unstemmed Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
title_short Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
title_sort analysis of organ-enriched micrornas in plasma as an approach to development of universal screening test: feasibility study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867418/
https://www.ncbi.nlm.nih.gov/pubmed/24330742
http://dx.doi.org/10.1186/1479-5876-11-304
work_keys_str_mv AT sheinermankiras analysisoforganenrichedmicrornasinplasmaasanapproachtodevelopmentofuniversalscreeningtestfeasibilitystudy
AT tsivinskyvladimirg analysisoforganenrichedmicrornasinplasmaasanapproachtodevelopmentofuniversalscreeningtestfeasibilitystudy
AT umanskysamuilr analysisoforganenrichedmicrornasinplasmaasanapproachtodevelopmentofuniversalscreeningtestfeasibilitystudy